Skip to content

Effects of preoperative radiotherapy to prevent postoperative recurrance of resectable hepatocellular carcinoma with high risk of microvacular invasion: A prospective randomized controlled trial

Effects of preoperative radiotherapy to prevent postoperative recurrance of resectable hepatocellular carcinoma with high risk of microvacular invasion: A prospective randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005562
Enrollment
Unknown
Registered
2014-11-03
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

A:preoperative radiotherapy+three weeks rest+radical resection
B:radical resection

Sponsors

Eastern Hepatobiliary Surgical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 70 years old male or female hepatocellular carcinoma patient; 2. karnofsky score 0-2; 3. liver function is Child-Pugh A or B; 4. single tumor; 5. with high-risk of microvascular invasion, no extrahepatic metastasis; 6. vascular invasion; no Portal vein tumor thrombus; 8. the liver volume of clinical target volume(CTV) in radiotherapy is less than the total liver volume 2/3; 9. Patients should sign the informed consent of this study.

Exclusion criteria

Exclusion criteria: 1. Operation resection scope beyond "Primary liver cancer diagnosis and treatment standard 2011"; 2. unradical resection of liver tumors; 3. Progress of tumor after radiotherapy can not be radical operated; 4. before enrollment received chemotherapy, radiotherapy, biological therapy, or participated in any other drug or therapy clinical trials by the instrument; 5. Liver, kidney and heart dysfunction; 6. the liver volume of clinical target volume(CTV) in radiotherapy is more than the total liver volume 2/3; 7. Researchers believe that those who should not participate in this trial.

Design outcomes

Primary

MeasureTime frame
Overall survival;radiographic parameters;Recurrent rates and Survival rates in 1,2,3,5 year;

Secondary

MeasureTime frame
Alpha fetoprotein;Liver function;

Contacts

Public ContactCheng Shuqun, Zheng Yaxin

Eastern Hepatobiliary Surgical Hospital

328604587@qq.com.cn+86 021 81875252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026